Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
- Precedex Gets 1st Designation as Drug for Specific Use
March 25, 2022
- MHLW Study Group Kicks Off Discussions on Use of Pseudonymously Processed Information
March 25, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
- CEFP Calls for Planned Healthcare Investments over Years
March 24, 2022
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
- PMDA to Publish Examples of Shortfalls Found in GMP Inspections
March 24, 2022
- Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
- Alexion’s Bleeding Antidote to Be Approved as Early as This Month
March 24, 2022
- Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
- Ensure Appropriate Care System for Post-COVID Vaccination Symptoms: MHLW Panels
March 23, 2022
- PMDA to Launch “GMP Roundtable” with Academia, Industry
March 23, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- MHLW to Order Label Revision for Somatropin, IFNβ-1a/1b Preparations
March 23, 2022
- Safety Panel OKs FY2022 Survey on US, EU Quality Control Systems, Questions Lagevrio Measures
March 22, 2022
- Conduct Yearly Surprise GMP Inspections for High-Risk Sites: MHLW
March 22, 2022
- Veklury Expands Label for Mild COVID-19
March 22, 2022
- MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…